Reuters Market Eye - Sun Pharmaceutical Industries
First instance of an Indian company taking global rights for a novel drug, traders say.
Deal strengthens Sun's presence in the U.S. skin market, also boosts revenue potential, traders add.
(Reporting by Abhishek Vishnoi)